|
Eag1 expression and clinicopathological characteristics. |
||
| Number of Tumours (%) |
Eag1 expression (%) |
|
|
|
||
| Sex |
||
| Male |
54 (45%) |
35 (65%) |
| Female |
67 (55%) |
51 (76%) |
| Age (years) |
||
| < 14 |
11 (9%) |
9 (82%) |
| 15 – 34 |
19 (16%) |
14 (74%) |
| 35 – 64 |
65 (54%) |
46 (71%) |
| > 65 |
26 (21%) |
17 (65%) |
| Histology |
||
| Fibrosarcoma |
12 (10%) |
8 (67%) |
| Leiomyosarcoma |
26 (22%) |
19 (73%) |
| Liposarcoma |
32 (26%) |
18 (56%) |
| Malignant fibrous histiocytoma |
22 (18%) |
18 (81%) |
| Rhabdomyosarcoma |
17 (14%) |
14 (82%) |
| Synovial sarcoma |
12 (10%) |
9 (75%) |
| Grade |
||
| Low |
70 (58%) |
49 (70%) |
| Moderate |
23 (19%) |
15 (65%) |
| High |
28 (23%) |
21 (75%) |
| Size |
||
| < 5 cm |
74 (61%) |
52 (70%) |
| > 5 cm |
47 (39%) |
33 (70%) |
| Site |
||
| Primary |
76 (63%) |
57 (75%) |
| Recurrence |
32 (26%) |
18 (56%) |
| Metastasis |
13 (11%) |
11 (85%) |
|
|
||
| Total |
121 |
86 (71%) |
Mello de Queiroz et al. Molecular Cancer 2006 5:42 doi:10.1186/1476-4598-5-42 |
||